1. Antibody-drug Conjugate/ADC Related
  2. ADC Linker

ADC Linker

Antibody-drug conjugates (ADCs) consist of a desirable monoclonal antibody, an active cytotoxic drug and an appropriate linker. An appropriate linker between the antibody and the cytotoxic drug provides a specific bridge, and thus helps the antibody to selectively deliver the cytotoxic drug to tumor cells and accurately releases the cytotoxic drug at tumor sites. In addition to conjugation, the linkers maintain ADCs’ stability during the preparation and storage stages of the ADCs and during the systemic circulation period.

The ADCs currently undergoing clinical evaluation contain linkers are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, such as reduction in the cytoplasm, exposure to acidic conditions in the lysosome, or cleavage by specific proteases within the cell. Noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule, which will retain the linker and the amino acid by which it was attached to the antibody.

The selection of linker is target dependent, based on the knowledge of the internalization and degradation of the antibody-target antigen complex, and a preclinical in vitro and in vivo activity comparison of conjugates. Moreover, the choice of a linker is also influenced by which cytotoxin is used, as each molecule has different chemical constraints, and frequently the drug structure lends itself to a specific linker.

ADC Linker 相关产品 (8):

Cat. No. Product Name Effect Purity
  • HY-20336
    Mc-Val-Cit-PABC-PNP是可用组织蛋白酶切割的ADC多肽连接桥。 FDA批准的药物brentuximab vedotin采用了该接头。
  • HY-78738
    MC-Val-Cit-PAB 99.56%
    MC-Val-Cit-PAB是可被组织蛋白酶切割的ADC连接桥,用于制备抗体-药物偶联物。 美国FDA批准的药物,如布伦替卡韦,血清素使用了该连接桥。
  • HY-41189
    Fmoc-Val-Cit-PAB-PNP是一种多肽前体药物连接子,是抗体偶联药物 (ADC) 的常用连接桥
  • HY-12362
    Val-cit-PAB-OH 99.35%
  • HY-21210
    6-Quinoxalinecarboxylic acid, 2,3-bis(bromomethyl)-
    6-Quinoxalinecarboxylic acid, 2,3-bis(bromomethyl)- 是抗体偶联药物 (ADC) 的连接桥。
  • HY-78961
    6-Maleimidohexanoic acid N-hydroxysuccinimide ester 99.96%
    6-Maleimidohexanoic acid N-hydroxysuccinimide ester(ECMS)是抗体偶联药物(ADC)中常用保护基团。
  • HY-19318
  • HY-20560